Plumbagin shows anticancer activity in human osteosarcoma (MG-63) cells via the inhibition of s-phase checkpoints and down-regulation of c-myc

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 8, 2015, Pages 14432-14439

  Yan, Chao Hua ^a   Li, Feng ^a   Ma, Yuan Chen ^b  

^a Jiujiang No 1 People's Hospital   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

CDK2; Cyclin A; Osteosarcoma; P53; Phosphorylation; Plumbagin

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE 2; MYC PROTEIN; PLUMBAGIN; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CHEMOLUMINESCENCE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; OSTEOSARCOMA; PHASE CONTRAST MICROSCOPY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

EID: 84943635710     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Acchiapati G, Randelli G and Randelli M. Observations on osteogenous- osteogenic sarcoma. Arch Orthop 1965; 78: 57-156.
2. Dix D, McDonald M and Cohen P. Adolescent bone cancer: is the growth spurt implicated? Eur J Cancer Clin Oncol 1983; 19: 859-860.
3. Soloviev I. On the relationship between the rate of skeleton growth and occurrence of primary osteogenic sarcoma. Vopr Onkol 1969; 15: 3-7.
4. Wilimas J, Barrett G and Pratt C. Osteosarcoma in two very young children. Clin Pediatr 1977; 16: 548-551.
5. Huvos AG. Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. Cancer 1986; 57: 1442-1449.
6. Goes M. Knochenwachstum und osteogenes sarckom. Strahlentherapie 1952; 89: 194-210.
7. Benson JE, Goske M, Han JS, Brodkey JS, Yoon YS. Primary osteogenic sarcoma of the calvaria. Am J Neuroradiol 1984; 5: 810-813.
8. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
9. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K and Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004; 73: 39-85.
10. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Rev 2005; 4: 988-1004.
11. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J, Dalla-Favera R. Non-transcriptional control of DNA replication by c-Myc. Nature 2007; 448: 445-451.
12. Kolligs FT, Kolligs B, Hajra KM, Hu G, Tani M, Cho KR, Fearon ER. γ-Catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of β-catenin. Genes Dev 2000; 14: 1319-1331.
13. van Es JH, Barker N and Clevers H. You Wnt some H, you lose some: oncogenes in theWnt signaling pathway. Curr Opin Genet Dev 2003; 13: 28-33.
14. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi JW, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Rochardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades OS. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. Cell 2011; 146: 904-917.
15. Macias E, Jin A, Deisenroth C, Bhat L, Mao H, Lindstrom MS, Zhang YP. An ARF-Independent c-MYC-Activated Tumor Suppression Pathway Mediated by Ribosomal Protein-Mdm2 Interaction. Cancer Cell 2010; 18: 231-243.
16. Calado DP, Sasaki Y, Godinho SA, Pellerin A, Kochert K, Sleckman BP, Alboran IM, Janz M, Rodig S, Rajewsky K. The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat Immunol 2012; 13: 1092-1100.
17. Taira N, Mimoto R, Kurata M, Yamaguchi T, Kitagawa M, Miki Y, Yoshida K. DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells. J Clin Invest 2012; 122: 859-872.
18. Kuo PL, Hsu YL and Cho CY. Plumbagin induces G2/M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Molecular Cancer Ther 2006; 5: 3209-3221.
19. Krishnaswamy M and Purushothaman KK. Plumbagin: A study of its anticancer, antibacterial and antifungal properties. Indian J Exp Biol 1980; 18: 876-877.
20. Singh UV and Udupa N. Reduced toxicity and enhanced antitumor efficacy of betacyclodextrin plumbagin inclusion complex in mice bearing Ehrlich ascites carcinoma. Indian J Physiol Pharmacol 1997; 41: 171-175.
21. Devi PU, Rao BS and Solomon FE. Effect of plumbagin on the radiation induced cytogenetic and cell cycle changes in mouse Ehrlich ascites carcinoma in vivo. Indian J Exp Bio 1998; 36: 891-895.
22. Hazra B, Sarkar R, Bhattacharyya S, Ghosh PK, Chel G and Dinda B. Synthesis of plumbagin derivatives and their inhibitory activities against Ehrlich ascites carcinoma in vivo and Leishmania donovani Promastigotes in vitro. Phytother Res 2002; 16: 133-137.
23. Sandur SK, Ichikawa H, Sethi G, Ahn KS and Aggarwal BB. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. Biol Chem 2006; 281: 17023-17033.
24. Ouyang ZX and Li XA. Inhibitory effects of tamoxifen and doxorubicin, alone and in combination, on the proliferation of the MG63 human osteosarcoma cell line. Oncol Lett 2013; 6: 970-976.
25. Gomathinayagam R, Sowmyalakshmi S, Mard-hatillah F, Kumar R, Akbarsha MA and Damodaran C. Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. Anticancer Res 2008; 28: 785-792.
26. Lee JH, Yeon JH, Kim H, Roh W, Chae J, Park Ho and Kim DM. The natural anticancer agent plumbagin induces potent cytotoxicity in MCF-7 human breast cancer cells by inhibiting a PI-5 kinase for ROS generation. PLoS One 2012; 7: e45023.
27. Singh RP, Dhanalakshmi S and Agarwal R. Phytochemicals as Cell Cycle Modulators A Less Toxic Approach in Halting Human Cancers. Cell Cycle 2012; 1: 156-161.
28. Toogood PL. Progress toward the development of agents to modulate the cell cycle. Curr Opin Chem Biol 2002; 6: 472-478.
29. Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Nahrmann YB, Lechel A, Rudolph KL, Langer R, Slotta-Huspenina J, Bader FG, Costa OP, Neurath MF, Meining A, Kirchner T, Greten FR. Loss of p53 in Enterocytes Generates an Inflammatory Microenvironment Enabling Invasion and Lymph Node Metastasis of Carcinogen-Induced Colorectal Tumor. Cancer Cell 2013; 23: 93-106.
30. Halaby MJ, Hakem A, Li L, Ghamrasni SE, Venkatesan S, Hande PM, Sanchez O, Hakem R. Synergistic Interaction of Rnf8 and p53 in the Protection against Genomic Instability and Tumorigenesis. PLoS Genet 2013; 9: e1003259.
31. Biroccio M, Porru A, Rizzo E, Salvati E, D’Angelo C, Orlandi A, Passeri D, Franceschin M, Stevens MF, Gilson E, Beretta G, Zupi Gabriella, Pisano C, Zunino F, Leonetti C. DNA Damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents. Clin Cancer Res 2011; 17: 2227-2236.
32. Shimizu T, Ishikawa T, Sugihara E, Kuninaka S, Miyamoto T, Mabuchi Y, Matsuzaki Y, Tsunoda T, Miya F, Morioka H, Nakayama R, Kobayashi E, Toyama Y, Kawai A, Ichikawa H, Hasegawa T, Okada S, Ito T, Ikeda Y, Suda T, Saya H. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 2010; 29: 5687-5699.
33. Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, Kerrerling RP, Sukov WR, Kanehira K, Chen B, Geiger XJ, Andorfer CA, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow JR, Harris LN, Ingle JN, Lingle WL, Reinholz MM. C-MYC Alterations and Association with Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. J Clin Oncol 2011; 29: 651-659.
34. Wu Q, Fan CD, Chen TF, Liu CR, Mei WJ, Chen SD, Wang BG, Chen YY, Zheng WJ. Microwave-assisted synthesis of arene ruthenium (II) complexes that induce S-phase arrest in cancer cells by DNA damage-mediated p53 phosphorylation. Eur J Med Chem 2013; 63: 57-63.
35. Xie XK, Yang DS, Ye ZM and Tao HM. Recombinant Antisense C-myc Adenovirus Increase in vitro Sensitivity of Osteosarcoma MG-63 Cells to Cisplatin. Cancer Invest 2006; 24: 1-8.
36. Xie XK, Yang DS, Ye ZM and Tao HM. Enhancement Effect of Adenovirus-Mediated Antisense c-myc and Caffeine on the Cytotoxicity of Cisplatin in Osteosarcoma Cell Lines. Chemotherapy 2009; 55: 433-440.